Benlysta | belimumab
Drug Class: B-cell inhibitor
Manufacturer: Human Genome Sciences
Approval date: March 2011
What is Benlysta
Benlysta is a man-made antibody that reduces the activity of immune cells (B-cells) in patients with systemic lupus erythematosus (SLE or lupus). Antibodies produced by defective B-cells contribute to development of SLE.
What does Benlysta treat
Benlysta is used for the treatment of adults with active, antibody-positive SLE and receiving other SLE therapies.
How effective is Benlysta
What are interesting facts about Benlysta
10 mg/kg intravenous infusion at 2-week intervals for 3 doses, then every 4-weeks. Each infusion lasts one hour.
What is the cost of Benlysta
Each vial cost about $1477.26 and the yearly cost is about $35,000 without insurance.
What are the side effects of Benlysta
Common: Infusion reactions, nausea, diarrhea, vomiting, fever, cough (bronchitis), insomnia, leg or arm pain, migraine, and sore throat
Serious: Infections, heart problems, depression, suicide, cancers
Benlysta drug interactions
How to obtain patient assistance for Benlysta
Contact the Benlysta Co-pay Assistance program
References: Benlysta FDA Prescribing Information and Medication Guide
The material on this site is for information only and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
Comment on this article or post an article by joining the RxEconsult community.
Please Share on Your Social Networks